Localized Surgical Therapy and Surveillance

  • Manish I. PatelEmail author
  • Paul D. Sved


Localized surgical therapy and surveillance examines the evidence and practice of two of the most important aspects of management of localized bladder cancer. The first part, surgical therapy, comprises preoperative assessment (including preoperative imaging studies, laboratory investigations, and antibiotic prophylaxis) followed by transurethral resection of bladder tumor. This section explores the principles of TURBT, including resection depth, staged resections, and bladder drainage. Specific circumstances such as tumors at the ureteral orifices, lateral/anterior walls, within diverticulae and reresection are specifically addressed.

The second part of this chapter, surveillance, examines the evidence and practice of surveillance of NMIBC following resection. This includes a discussion of risk stratification, so appropriate surveillance strategies can be correctly applied. Specific areas such as cystoscopy schedule, first cystoscopy, further cystoscopies, methods to improve surveillance cystoscopies, use of urinary markers, imaging and upper tract evaluation are discussed in more detail.


Surveillance Cystoscopy Bladder tumor Risk group Transurethral resection Technique Follow up 



Non-muscle-invasive bladder cancer


Transurethral resection of bladder tumor


Urinary tract infection


European organization for the research and treatment of cancer


Carcinoma in situ


Bladder mapping


European association of urology


Papillary neoplasm of low malignant potential


Fluorescent cystoscopy


White light


Upper tract tumor


  1. 1.
    Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63(1):4–15. PubMed PMID: 23083902.PubMedCrossRefGoogle Scholar
  2. 2.
    Cousins J, Howard J, Borra P. Principles of anaesthesia in urological surgery. BJU Int. 2005;96(2):223–9. PubMed PMID: 16001964.PubMedCrossRefGoogle Scholar
  3. 3.
    Alsaywid BS, Smith GH. Antibiotic prophylaxis for transurethral urological surgeries: systematic review. Urol Ann. 2013;5(2):61–74. PubMed PMID: 23798859. Pubmed Central PMCID: 3685747.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Wolf Jr JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179(4):1379–90. PubMed PMID: 18280509.PubMedCrossRefGoogle Scholar
  5. 5.
    Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34. PubMed PMID: 16399414.PubMedCrossRefGoogle Scholar
  6. 6.
    Pan D, Soloway MS. The importance of transurethral resection in managing patients with urothelial cancer in the bladder: proposal for a transurethral resection of bladder tumor checklist. Eur Urol. 2012;61(6):1199–203. PubMed PMID: 22464897.PubMedCrossRefGoogle Scholar
  7. 7.
    Furuse H, Ozono S. Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills. Int J Urol. 2010;17(8):698–9. PubMed PMID: 20649827.PubMedCrossRefGoogle Scholar
  8. 8.
    Solsona E, Iborra I, Ricos JV, Monros JL, Dumont R, Casanova J, et al. Recurrence of superficial bladder tumors in prostatic urethra. Eur Urol. 1991;19(2):89–92. PubMed PMID: 1902417.PubMedGoogle Scholar
  9. 9.
    Soloway MS, Patel J. Surgical techniques for endoscopic resection of bladder cancer. Urol Clin North Am. 1992;19(3):467–71. PubMed PMID: 1636231.PubMedGoogle Scholar
  10. 10.
    Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36–44. PubMed PMID: 22981672.PubMedCrossRefGoogle Scholar
  11. 11.
    Nieder AM, Meinbach DS, Kim SS, Soloway MS. Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting. J Urol. 2005;174(6):2307–9. PubMed PMID: 16280830.PubMedCrossRefGoogle Scholar
  12. 12.
    Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–30. PubMed PMID: 17993339.PubMedCrossRefGoogle Scholar
  13. 13.
    Ramirez-Backhaus M, Dominguez-Escrig J, Collado A, Rubio-Briones J, Solsona E. Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep. 2012;13(2):109–14. PubMed PMID: 22367558.PubMedCrossRefGoogle Scholar
  14. 14.
    Mariappan P, Smith G, Lamb AD, Grigor KM, Tolley DA. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol. 2007;177(3):867–75. PubMed PMID: 17296362. Discussion 75.PubMedCrossRefGoogle Scholar
  15. 15.
    Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–31. PubMed PMID: 12074794.PubMedCrossRefGoogle Scholar
  16. 16.
    Han KS, Joung JY, Cho KS, Seo HK, Chung J, Park WS, et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol. 2008;22(12):2699–704. PubMed PMID: 19025393.PubMedCrossRefGoogle Scholar
  17. 17.
    Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843–9. PubMed PMID: 19524354.PubMedCrossRefGoogle Scholar
  18. 18.
    Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162(1):74–6. PubMed PMID: 10379743.PubMedCrossRefGoogle Scholar
  19. 19.
    Dutta SC, Smith Jr JA, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166(2):490–3. PubMed PMID: 11458053.PubMedCrossRefGoogle Scholar
  20. 20.
    Vasdev N, Dominguez-Escrig J, Paez E, Johnson MI, Durkan GC, Thorpe AC. The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. Ecancermedicalscience. 2012;6:269. PubMed PMID: 22988482. Pubmed Central PMCID: 3436501.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol. 2007;177(1):75–9. PubMed PMID: 17162005. Discussion 9.PubMedCrossRefGoogle Scholar
  22. 22.
    Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9 Pt B):1242–6. PubMed PMID: 19035888.PubMedCrossRefGoogle Scholar
  23. 23.
    Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175(5):1641–4. PubMed PMID: 16600720.PubMedCrossRefGoogle Scholar
  24. 24.
    Gudjonsson S, Blackberg M, Chebil G, Jahnson S, Olsson H, Bendahl PO, et al. The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS). BJU Int. 2012;110(2 Pt 2):E41–5. PubMed PMID: 22035276.PubMedCrossRefGoogle Scholar
  25. 25.
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997–1008. PubMed PMID: 21458150.PubMedCrossRefGoogle Scholar
  26. 26.
    Hautmann RE, Abol-Enein H, Davidsson T, Gudjonsson S, Hautmann SH, Holm HV, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: urinary diversion. Eur Urol. 2013;63(1):67–80. PubMed PMID: 22995974.PubMedCrossRefGoogle Scholar
  27. 27.
    Levi AW, Potter SR, Schoenberg MP, Epstein JI. Clinical significance of denuded urothelium in bladder biopsy. J Urol. 2001;166(2):457–60. PubMed PMID: 11458047.PubMedCrossRefGoogle Scholar
  28. 28.
    O'Neil BB, Lowrance WT. Office-based bladder tumor fulguration and surveillance: indications and techniques. Urol Clin North Am. 2013;40(2):175–82. PubMed PMID: 23540776.PubMedCrossRefGoogle Scholar
  29. 29.
    Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5. PubMed PMID: 16442208. Discussion 75–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol. 2002;168(3):978–80. PubMed PMID: 12187203.PubMedCrossRefGoogle Scholar
  31. 31.
    Donat SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol. 2004;171(2 Pt 1):636–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423–30. PubMed PMID: 21621906.PubMedCrossRefGoogle Scholar
  33. 33.
    Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–203. PubMed PMID: 19758621.PubMedCrossRefGoogle Scholar
  34. 34.
    Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol. 2002;167(4):1634–7. PubMed PMID: 11912378.PubMedCrossRefGoogle Scholar
  35. 35.
    Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer. 1995;31A(11):1840–6. PubMed PMID: 8541110.PubMedCrossRefGoogle Scholar
  36. 36.
    Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol. 1989;142(2 Pt 1):284–8. PubMed PMID: 2501516.PubMedGoogle Scholar
  37. 37.
    Herr HW. Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol. 1991; 145(1):40–3. PubMed PMID: 1984096. Discussion 3–4.PubMedGoogle Scholar
  38. 38.
    Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol. 2000;164(3 Pt 1):685–9. PubMed PMID: 10953125.PubMedCrossRefGoogle Scholar
  39. 39.
    Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013l;64(4):639--53. PubMed PMID: 23827737.Google Scholar
  40. 40.
    Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl. 1995;172:33–6. PubMed PMID: 8578253.PubMedGoogle Scholar
  41. 41.
    Holmang S, Strock V. Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years? Eur Urol. 2012;61(3): 503–7. PubMed PMID: 22119022.PubMedCrossRefGoogle Scholar
  42. 42.
    Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol. 2005;173(4): 1108–11. PubMed PMID: 15758711.PubMedCrossRefGoogle Scholar
  43. 43.
    Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986;135(5):920–2. PubMed PMID: 3959241.PubMedGoogle Scholar
  44. 44.
    Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM, et al. Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol. 1999;162(6):1946–50. PubMed PMID: 10569544.PubMedCrossRefGoogle Scholar
  45. 45.
    Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14(4):1–331. iii–iv. PubMed PMID: 20082749.CrossRefGoogle Scholar
  46. 46.
    Cauberg EC, Kloen S, Visser M, de la Rosette JJ, Babjuk M, Soukup V, et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology. 2010;76(3):658–63. PubMed PMID: 20223505.PubMedCrossRefGoogle Scholar
  47. 47.
    Loidl W, Schmidbauer J, Susani M, Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol. 2005;47(3):323–6. PubMed PMID: 15716195.PubMedCrossRefGoogle Scholar
  48. 48.
    Herr HW, Donat SM. Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy. BJU Int. 2011;107(3):396–8. PubMed PMID: 20707789.PubMedCrossRefGoogle Scholar
  49. 49.
    Dalbagni G, Rechtschaffen T, Herr HW. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? J Urol. 1999;162(3 Pt 1):708–9. PubMed PMID: 10458348.PubMedCrossRefGoogle Scholar
  50. 50.
    Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol. 2007;177(4):1277–82. PubMed PMID: 17382711. Discussion 82.PubMedCrossRefGoogle Scholar
  51. 51.
    Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012;62(2):290–302. PubMed PMID: 22609313.PubMedCrossRefGoogle Scholar
  52. 52.
    Cohan RH, Caoili EM, Cowan NC, Weizer AZ, Ellis JH. MDCT Urography: Exploring a new paradigm for imaging of bladder cancer. AJR Am J Roentgenol. 2009;192(6):1501–8. PubMed PMID: 19457811.PubMedCrossRefGoogle Scholar
  53. 53.
    Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Huguet-Perez J, Vicente-Rodriguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol. 2000;164(4):1183–7. PubMed PMID: 10992362.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Westmead HospitalUniversity of SydneyWestmeadAustralia
  2. 2.Royal Prince Alfred HospitalUniversity of SydneyNewtownAustralia

Personalised recommendations